Updated Investor Presentation
Released
Released
Announcement PDF
MRI Imaging
Agents
for Cancer
Detection
A Breakthrough in
Molecular Magnetic
Resonance Imaging
Imagion Biosystems Limited
ASX:IBX
1
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Forward Looking Statements
This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This pres entation does not constitute or form part of, and should not be construed as,
an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any memb er of its group nor should it or any part of it form the basis of, or be relied on in
connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or
commitment whatsoever.
This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a
general nature and does not purport to be complete nor does it contain all the information which a prospective investor shoul d consider when making an investment decision. Each recipient of this
presentation should make its own enquiries and investigations regarding all information in this presentation including but no t limited to the assumptions, uncertainties and contingencies which may affect
future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been pr epared without taking account of any person’s investment objectives, financial
situation or particular needs. Before making an investment decision, prospective investors should consider the appropriatenes s of the information having regard to their own objectives, financial situation and
needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis
of the information.
The information included in this presentation has been provided to you solely for your information and background and is subj ect to updating, completion, revision and amendment and such information may
change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any
opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implie d, is made as to the fairness, currency, accuracy, reasonableness or completeness
of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers an d employees) accepts any liability and Imagion, its shareholders, its related bodies
corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this
presentation or its contents.
This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition,
performance, prospects, growth, strategies and the industry in which Imagion operates. These forward -looking statements are subject to risks, uncertainties and assumptions and other factors, many of which
are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance,
prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from t hose made in or suggested by the forward-looking statements contained in this
presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax
treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to)
Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review,
update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which
these forward-looking statements are based, except as required by applicable law or regulation.
This presentation and any materials distributed in connection with this presentation are not directed to, or intended for dis tribution to or use by, any person or entity that is a citizen or resident or located in
any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrar y to law or regulation or which would require any registration or licensing within such
jurisdiction.
The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession thi s presentation comes should inform themselves about and observe any such
restrictions.
2
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Clinical Pipeline
MagSense® mMRI Technology
Transforming molecular imaging
HER2+ Breast Cancer
$500M TAM *
Ready for Phase 2
Specific
Provides molecular
confirmation of cancer, not just
“suspicion”.
Safer
No radioactivity.
Low dose produces contrast.
Better Patient Care
Reduces need for biopsies and
can detect small tumors.
3
IBX Investor Deck
MRI-based Detection
Compatible across 50k+ MRI
scanners in use globally.
Prostate Cancer
$1B TAM *
Ready for IND/Phase 1
Platform Technology
Fits clinical workflow and can be
used across many cancers.
Theranostics potential.
Ovarian Cancer
$500MTAM *
Ready for IND/Phase 1
* Refer to slide 8 for market details
Copyright March 2025
| ImagionBiosystems.com
An Unmet Need in Cancer
Diagnosis
Conventional Imaging provides anatomical context
but is not specific and can only identify a region of
interest.
Screening
Imaging
Biopsy
Indicates risk, but nondiagnostic. Requires
confirmation before
treatment.
Identify “suspicious
lesions” but can’t
distinguish between
benign or malignant.
Painful, complicated, error prone and
challenging. Pathology assessments can
take days.
MagSense® Imaging uses molecularly targeted
imaging agents to produce a distinct image pattern
indicating the presence of a tumor.
4
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Pre-Dose
How MagSense® molecular
MRI works
MagSense particles are coated with unique
targeting moiety and administered before MRI
MagSense particles only bind to target type of
cancer cells, if present
Post-Dose
MagSense® nanoparticles enable molecular
imaging by producing an identifiable change in
image contrast when cancer cells are present
Pre-Dose
Post-Dose
~30% Change in
intensity
MagSense produces an identifiable change in
image contrast which is easily detected
5
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
mMRI Enables AI Detection
Unique quantitative signature allows
for Artificial Intelligence and Machine
Learning algorithms for automated
detection.
Existing iron-based AI diagnostics
already show proof of concept.
6
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Use Cases and
Global Markets
7
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Clinical Development Pipeline
Nodal Metastases in HER2+
Breast Cancer
Primary Tumor Detection of
Prostate Cancer
Early Detection of Ovarian
Cancer
$500M Market Opp. *
Ready forIND/Phase 2
$1.1B Market Opp. *
Ready forIND/Phase 1
$500M Market Opp. *
Ready forIND/Phase 1
• 1M+ Prostate biopsies/year in U.S.
• 75% of cases diagnosed at late stage.
• mpMRI has a >50% False Positive rate and
a >15% False Negative rate.
• CA-125 blood tests indicate risk, but are
not predictive of disease.
• Lymph node analysis is SoC for cancer
staging.
• PSMA-PET is not typically used for
primary tumor detection and subjects
patients to radioactivity.
• “Watchful waiting” by ultrasound is the
existing SoC.
• Existing SoC (ultrasound) is regionally
limited and non-diagnostic.
• Current SoC results in significant
unnecessary biopsies with FP/FN.
• 400,000 HER2+ Breast Cancer diagnoses
annually (~20% of all BC).
• HER2+ tumors tend to be one of the more
aggressive forms of Breast Cancer.
8
IBX Investor Deck
* Market Opportunity calculated as total global incidence x expected market price ($1200)
Global incidence data from market research reports
• >300,000 women/yr. diagnosed with
ovarian cancer; ~2/3rds die from the
disease.
Copyright March 2025
| ImagionBiosystems.com
Key Business Factors for MagSense®
Imaging Agents
$5.0
Complications
$4.5
High Gross Margin – Imaging agent can be produced in commercial
quantities by standard drug manufacturing methods at costs that support
commercial partnering.
Long Shelf Life – Clinical lots have shown > 2yr stability and can be
stored and supplied by the hospital pharmacy like GBCAs.
Fits Existing Workflow – Expands use of MRI within existing clinical
workflows; compatible across 50,000+ scanners globally.
Transformative – AI detection could improve “diagnostic” utility of
imaging and add value to the radiologist’s role in patient management.
9
IBX Investor Deck
$0.3
$0.2
SLNB
$4.0
Costs in Millions (USD)
Value Based Reimbursement – Health economics supports $1,200 to
$1,500 reimbursement rate, while still saving costs.
Costs by Category Associated with SOC versus
MagSense
$100,000 saved per 1,000 patients
$1.0
$3.5
$3.0
ALND
$2.5
$2.5
$0.5
$0.0
$2.0
$1.5
$1.0
$0.5
$0.0
$0.5
MRI
Ultrasound Guided FNA
Biopsy
$0.6
$2.1
Clincal
Assessment/MagSense
$0.5
$0.3
$0.3
SOC
MagSense
Copyright March 2025
| ImagionBiosystems.com
Clinical Development Plan and Key Milestones
Completed
HER2+
Breast
Cancer
2026
2025
2027
Key Next Steps
Phase 3
File IND and initiate
Phase 2 study for HER2
imaging agent
IND
Phase 2
Phase 1
Dose and Image Protocol Optimization
IND
Ovarian
Cancer
Prostate
Cancer
10
Pre-Clinical
IND-enabling
Phase 1
Phase 2
Human Safety
IND
Pre-Clinical
MagSense® Imaging Agents Intro
IND-enabling
Phase 1
Phase 2
Complete IND
enabling studies for
Prostate Cancer and
Ovarian Cancer to
enter clinical phase.
Human Safety
Copyright March 2025
| ImagionBiosystems.com
Investment
Rationale
11
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Molecular Imaging will Drive
MRI Growth
1. Global cancer incidence to rise 77% by 20501
2. Screening & Diagnostic Imaging market growing at 6.7% CAGR2
3. Molecular imaging to-date limited to methods using radioactivity due to MRI
lacking specificity.
4. Almost 100% of contrast media products achieve regulatory approval.
5. MagSense® imaging agents are completely differentiated and fit the
existing medical imaging and contrast media business model.
12
IBX Investor Deck
Sources: JAMA Oncology. 2022. Medicare Payment Advisory Commission (MedPAC) and Centers for Medicare and
Medicaid Services (CMS). Mordor Intelligence. Global Contrast Media Market
Copyright March 2025
| ImagionBiosystems.com
Comparable Transactions
Strategic Partnering
Incumbents continue making attractive deals for differentiated clinical-stage assets
Acquirer
13
IBX Investor Deck
Target
Value AUD
Year
Notes
$18M
2024
Strategic investment. Part of $70M AUD
financing transaction.
$310M
2024
$35M revenue at time of transaction.
Breast cancer
$1.6B
2018
Imuno-oncology agent. Acquired
following successful Phase 3.
$328M Est.
2019
All stock acquisition. Estimated market
cap at transaction date.
$3.9B
2018
Acquired in Phase 3, pending FDA
clearance. Radioligand therapy.
Copyright March 2025
| ImagionBiosystems.com
2025 – 2026 Corporate Focus
Objectives for Value Creation
Complete Phase 2 Study
for HER2 Breast Cancer
Program
• Obtain IND or like multinational regulatory jurisdiction and commence Phase 2 of clinical investigation
• Complete the Phase 2 study in 18-24 months
• Establish AI-based autodetection algorithms to improve sensitivity and accuracy of detection
Advance Prostate Cancer
Program to clinical phase
• Complete IND-enabling preclinical toxicology studies
• Submit IND, or like regulatory filing
• Initiate a Phase 1 study
Advance Ovarian Cancer
Program to clinical phase
• Complete IND-enabling preclinical toxicology studies
• Submit IND, or like regulatory filing
• Initiate a Phase 1 study
Corp Development
14
IBX Investor Deck
• Continue to meet with prospective global strategic industry and instrument partners
• Present data at key imaging meetings
• Identify regional commercial licensing opportunities
Copyright March 2025
| ImagionBiosystems.com
Corporate Summary
Highlights
• US$2.1B Market Opportunity
• Highly differentiated product lineup is first-of-its-kind in
molecular imaging.
• Operating as a lean virtual biotech with low fixed G&A
costs.
• Strategic partnering commercial model with potential for
non-dilutive income and cost sharing.
Upcoming Project Milestones
• IND approval for Phase 2 study of HER2 Breast Cancer
Capital Structure and Funding
• AUD $2.67 cash on hand as of 31 Dec 2024
• AUD $10.78M in funding available through Convertible
Financing facility
• 201,341,415 fully paid ordinary shares - largely retail
shareholder base
• Initiate IND-enabling studies for Prostate and Ovarian
Cancer to advance to the clinic
15
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Imagion
Leadership
Robert Proulx
Ward Detwiler
Melanie Leydin CA FGIA
Brett Mitchell
Executive Chairman
Chief Business Officer
Company Secretary & Non-Executive
Director
Non-Executive Director
Robert is an operationally oriented
executive with over 30 years in life science
& medical device product development &
commercialization and has led the
company through recent restructuring and
recapitalization.
Experienced early stage
technology executive with a
track record of bringing
health technologies from
concept to market.
Melanie is a Chartered Accountant
and a Fellow of the Governance Institute of
Australia with over 30
years of experience in Accounting
and over 20 years in Board positions,
currently the Managing Director of Vistra
Australia.
Mr. Mitchell is an experienced corporate
finance executive with
over 25 years of experience in the
venture capital and equity capital
markets, leading transactions in the
mining, energy, technology and life
sciences sectors.
16
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
info@imagionbio.com | ASX:IBX
17
IBX Investor Deck
Copyright March 2025
| ImagionBiosystems.com
Share your feedback
Discover